Highlights NetraMark Holdings Inc.

Equities

AIAI

CA64119M1059

Market Closed - Canadian Securities Exchange Other stock markets 03:52:40 2024-05-10 pm EDT			5-day change	1st Jan Change
0.305 ^CAD	-6.15%		-4.69%	-12.86%

Apr. 10	Netramark's Ai-Based Clinical Solution Identifies Novel Lung and Colon Cancer Biomarkers and Patient Subpopulations	CI
Apr. 04	NetraMark Holdings Inc. announces appointment of Jeff Huntsman to its strategic advisory board	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Netramark's Ai-Based Clinical Solution Identifies Novel Lung and Colon Cancer Biomarkers and Patient Subpopulations	Apr. 10	CI
NetraMark Holdings Inc. Signs Contract with Pharmaceutical Company to Deliver Clinical Trial Insights Regarding Efficacy and Placebo Response	Mar. 12	CI
NetraMark Presenting New Data Showing Ability of its Proprietary NetraAI Clinical Trial Solution in PD Insights	Mar. 11	MT
NetraMark Holdings Inc. Announces the Presentation of New Data Demonstrating the Ability of its Proprietary NetraAI Clinical Trial Solution	Mar. 11	CI
NetraMark Holdings Inc. Signs Fourth Contract with Large Biopharmaceutical Company to Enhance Clinical Trial	Feb. 27	CI
NetraMark Holdings Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	Feb. 26	CI
Netramark Holdings Inc. Announces Presentations of New Data Demonstrating the Application of Its Netraai Clinical Solution to Data Sets of Less Than 400 Patients	Feb. 26	CI
NetraMark Holdings Inc. to Present New Data Supporting the Potential of Its Proprietary NetraAI Clinical Trial Solution to De-Risk Clinical Trials	Feb. 15	CI
NetraMark Holdings Inc. Announces Launch of the NetraAI Lab Offering	Feb. 12	CI
Netramark Holdings Inc. Signs Third Contract with Biopharmaceutical Company	Jan. 30	CI
NetraMark Holdings Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	Jan. 26	CI
NetraMark's Generative AI Discovers Novel Rare Disease Drug Targets and Unique Patient Subpopulations That Could Substantially Improve Clinical Trial Success Rates	Jan. 16	CI
NetraMark Holdings Inc. Signs Two Contracts with Large Biopharmaceutical Company to Enhance Clinical Trial Insights	Dec. 20	CI
NetraMark Holdings Inc. Signs Master Service Agreement with Large Biopharmaceutical Company	23-10-31	CI
NetraMark Holdings Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	23-08-17	CI
NetraMark Holdings Increased Private Placement Financing; Uplisting to the OTCQB Market	23-06-07	MT
NetraMark Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	23-05-18	CI
Netramark, to Launch Clinical Trial De-Risking Technology That Integrates Chatgpt	23-05-16	CI
NetraMark Holdings Inc. Uncovers Unique Alzheimer's Disease Subtypes	23-03-15	CI
NetraMark Holdings Inc. Reports Earnings Results for the First Quarter Ended December 31, 2022	23-02-24	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights NetraMark Holdings Inc.

Equities

AIAI

CA64119M1059

Highlights

Filters